A Phase 3 interventional study of Obinutuzumab and Placebo in Systemic Lupus Erythematosus, sponsored by Hoffmann-La Roche. Active, not recruiting at 63 sites in 14 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche — 2 open to participants now, 4 under way, 1 of them phase 3. Lupus Erythematosus, Systemic · Hoffmann-La Roche.
Among the 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche, this one is the 2nd largest by enrollment, is the only one that started in 2021, is one of 4 in phase 3, and was the 9th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →2 of the 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche are open now, in 10 countries. Recruiting first, the newest first:
Genentech, Inc. · Sites in Australia, Brazil, China and 3 more countries
Ages 18–75
Hoffmann-La Roche · Sites in Argentina, Brazil, Colombia and 3 more countries
Ages 18+
By country, each count listing its studies:
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 5
First in 2005; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 303 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 65 across the 14 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
1 of the studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05835986Hoffmann-La RocheA First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus | 2027-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of obinutuzumab versus placebo in participants with active, autoantibody-positive systemic lupus erythematosus (SLE) who are treated with standard-of-care therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive obinutuzumab 1000 milligrams (mg) intravenous (IV) infusions on Day 1 and at Weeks 2, 24 and 26.
Drug: Obinutuzumab · Drug: Acetaminophen/Paracetamol · Drug: Diphenhydramine hydrochloride · Drug: Methylprednisolone
Placebo participants will receive obinutuzumab matched placebo on Day 1 and at Weeks 2, 24 and 26.
Drug: Placebo · Drug: Acetaminophen/Paracetamol · Drug: Diphenhydramine hydrochloride · Drug: Methylprednisolone
Obinutuzumab will be administered by IV infusion at a dose of 1000 mg on Day 1 and at Weeks 2, 24 and 26.
Also known as: Gazyva, GA101, RO5072759
Placebo matching obinutuzumab will be administered by IV on Day 1 and at Weeks 2, 24 and 26.
Drug page: Acetaminophen
Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.
Diphenhydramine 50 mg will be administered as premedication prior to infusions.
Methylprednisolone 80 mg IV will be administered as premedication prior to infusions.
Percentage of Participants Who Achieved SLE Responder Index (SRI4) at Week 52
Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of \>=4 points in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K); 2) No new systems or organs affected, as defined by \>=1 new British Isles Lupus Assessment Group (BILAG) A or \>=2 new BILAG B items compared with baseline; 3) No worsening from baseline of \>=0.30 points on a 3-point Physician's Global Assessment-Visual Analog Scale (PGA-VAS). SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).
Time frame: At Week 52
Percentage of Participants Who Achieved British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) at Week 52
Achieving BICLA was defined as all of the following: 1) Reduction of all baseline BILAG-2004 A items to B/C/D and baseline BILAG-2004 B items to C/D; 2) No new systems or organs affected, as defined by \>=1 new BILAG A or \>=2 new BILAG B items compared with baseline; 3) No net increase in SLEDAI-2K score from baseline; 4) No worsening from baseline of \>=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).
Time frame: At Week 52
Percentage of Participants Who Achieved Sustained Oral Corticosteroid Control (OCS) (<=7.5 mg/Day) From Week 40 Through Week 52
Sustained OCS was defined as all of the following: 1) No treatment with prednisone \>7.5 mg/day (or equivalent) from Week 40 through Week 52; 2) No receipt of intravenous, intramuscular, or intra-articular corticosteroids from Week 40 through Week 52. Participants who experienced intercurrent events, including major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy, or AE, were considered nonresponders.
Time frame: From Week 40 through Week 52
Percentage of Participants Who Achieved Sustained SRI(4) Response From Week 40 Through Week 52
Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of \>=4 points in the SLEDAI-2K; 2) No new systems or organs affected, as defined by \>=1 new BILAG A or \>=2 new BILAG B items compared with baseline; 3) No worsening from baseline of \>=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).
Time frame: From Week 40 Through Week 52
Percentage of Participants With SRI(6) Response at Week 52
Achieving SRI(6) was defined as all of the following: 1) Reduction from baseline of \>=4 points in the SLEDAI-2K; 2) No new systems or organs affected, as defined by \>=1 new BILAG A or \>=2 new BILAG B items compared with baseline; 3) No worsening from baseline of \>=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).
Time frame: At Week 52
Time to BILAG Flare Over 52 Weeks
BILAG flare was defined as the occurrence of \>=1 new BILAG A or \>=2 new BILAG B manifestations from the previous visit. BILAG Index assesses clinical signs, symptoms, and laboratory parameters related to SLE across 9 organ systems. Each organ system is scored alphabetically: A (severe disease), B (moderate disease), C (mild stable disease), D (inactive but previously active), and E (inactive and never affected). Participants who experienced major concomitant therapy violation, treatment failure requiring rescue medication, and lack of efficacy (regardless of discontinuation from treatment or study) were considered as having a flare at the time of the event. Participants who experienced early discontinuation from the blinded period due to reasons other than lack of efficacy and those who completed 52 week treatment period without flare were censored at the time of the event. Kaplan-Meier (KM) method was used to estimate the time to first BILAG flare.
Time frame: At Week 52
Percentage of Participants Who Achieved SRI(4) at Week 24
Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of \>=4 points in the SLEDAI-2K; 2) No new systems or organs affected, as defined by \>=1 new BILAG A or \>=2 new BILAG B items compared with baseline; 3) No worsening from baseline of \>=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).
Time frame: At Week 24
Percentage of Participants Who Achieved Clinical SRI(4) at Week 52
Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of \>=4 points in the SLEDAI-2K, excluding points from the immunologic components (low complement and elevated anti-dsDNA antibody; 2) No new systems or organs affected, as defined by \>=1 new BILAG A or \>=2 new BILAG B items compared with baseline; 3) No worsening from baseline of \>=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).
Time frame: At Week 52
Percentage of Participants Who Achieved SRI(4) at Week 52 on Low-dose of Corticosteroids
Achieving SRI(4) on low doses of corticosteroids was defined as all of the following: 1) Reduction from baseline of \>=4 points in SLEDAI-2K; 2) No new systems or organs affected, as defined by \>=1 new BILAG A or \>=2 new BILAG B items compared with baseline; 3) No worsening from baseline of \>=0.30 points on a 3-point PGA-VAS; 4) Prednisone \<=7.5 mg/day or equivalent. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).
Time frame: At Week 52
Percentage of Participants Who Achieved Lupus Low Disease Activity State (LLDAS) at Week 52
LLDAS response was defined as achievement of all of the following: 1) SLEDAI-2K \<=4; 2) No SLEDAI-2K activity in major organ systems (renal, central nervous system, cardiopulmonary, vasculitis, fever) and no BILAG hemolytic anemia or gastrointestinal activity; 3) No new SLEDAI-2K activity compared with the previous assessment PGA-VAS \<=1; 4) Current prednisone dose \<=7.5 mg/day or equivalent. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).
Time frame: At Week 52
Percentage of Participants Who Achieved Definition of Remission in SLE (DORIS) at Week 52
DORIS response was defined as achievement of all of the following: 1) Clinical SLEDAI-2K (cSLEDAI-2K) = 0, where cSLEDAI-2K is defined as total SLEDAI-2K score excluding anti-dsDNA and complement items; 2) PGA-VAS \<0.5; 3) Current prednisone dose \<=5 mg/day or equivalent. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor). Participants who experienced intercurrent events, including major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy or AE, were considered nonresponders.
Time frame: At Week 52
Change in Functional Assessment of Chronic Illness Therapy-fatigue (FACIT-F) Scale From Baseline to Weeks 24 and 52
The FACIT-F was a patient-completed questionnaire consisting of 13 items that assessed fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as: 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). Adjusted mean values have been reported. The analysis was performed using analysis of covariance (ANCOVA) model.
Time frame: Baseline, Weeks 24 and 52
Change in 36-Item Short Form Survey, Version 2 (SF-36 V2) Bodily Pain Domain Scale From Baseline to Weeks 24 and 52
The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status. Adjusted mean values have been reported. The analysis was performed using ANCOVA model.
Time frame: Baseline, Weeks 24 and 52
Change in SF-36 V2 Physical Component Summary Scale From Baseline to Weeks 24 and 52
The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and the MCS. The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status. Adjusted mean values have been reported. The analysis was performed using ANCOVA model.
Time frame: Baseline, Weeks 24 and 52
Change in Active Joint Count From Baseline to Weeks 24 and 52
Active joint was defined as a joint that is both swollen and tender. A 28-joint count of swollen and tender joints was performed in this study. Data after the first occurrence of intercurrent event (ICE), including major concomitant therapy violation, treatment failure requiring rescue medication or early discontinuation from the blinded period due to AE, death and lack of efficacy, was imputed using the worst post-baseline value from the following assessments: the last value available prior to the occurrence of the first ICE; all values available after the occurrence of the ICE. Participants with treatment discontinuation without any ICE above were evaluated under the treatment policy strategy. Adjusted mean values have been reported. The analysis was performed using ANCOVA model.
Time frame: Baseline, Weeks 24 and 52
Percentage of Participants Who Achieved a >=50% Reduction in Active Joint Counts at Each Study Visit, Among Participants With >=4 Active Joints at Baseline
Active joint was defined as a joint that is both swollen and tender. A 28-joint count of swollen and tender joints was performed in this study. Participants who experienced major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy or AE were considered non-responders.
Time frame: At Weeks 24, 28, 32, 36, 40, 44, 48 and 52
Percentage of Participants Who Achieved a >=50% Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity (CLASI) Total Activity Score at Each Study Visit
CLASI is a validated instrument for assessing cutaneous lupus erythematosus activity. It reports two global scores: one for current inflammatory activity (Total Activity Score), and one for damage (Total Damage Score). To calculate the total scores, trained assessors evaluate erythema, scale/hypertrophy, dyspigmentation, and scarring/atrophy/panniculitis at 13 anatomic locations plus additional assessments for mucosal lesions and alopecia. CLASI total activity score ranges from 0 to 70, with higher scores indicating increased disease severity. Participants who experienced major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy or AE were considered non-responders.
Time frame: At Weeks 24, 28, 32, 36, 40, 44, 48 and 52
Percentage of Participants Who Achieved Sustained OCS (<=5 mg/Day) From Week 40 Through Week 52
Sustained OCS was defined as all of the following: 1) No treatment with prednisone \>5 mg/day (or equivalent) from Week 40 through Week 52; 2) No receipt of intravenous, intramuscular, or intra-articular corticosteroids from Week 40 through Week 52. Participants who experienced intercurrent events, including major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy, or AE, were considered nonresponders.
Time frame: From Week 40 through Week 52
Cumulative Corticosteroid Use Through Week 52
Cumulative oral corticosteroid was represented in prednisone or equivalent only. The mean of the standardized area under the curve (AUC) through Week 52 have been reported. AUC was derived based on the actual dose participants have received. Standardized AUC was derived using AUC divided by days in study multiplied by 365.25 days for each participant.
Time frame: Up to Week 52
Annualized Flare Rate Through Week 52
BILAG flare was defined as the occurrence of \>=1 new BILAG A or \>=2 new BILAG B manifestations from the previous visit. BILAG Index assesses clinical signs, symptoms, and laboratory parameters related to SLE across 9 organ systems. Each organ system is scored alphabetically: A (severe disease), B (moderate disease), C (mild stable disease), D (inactive but previously active), and E (inactive and never affected). The number of flares over the 52-week blinded treatment period has been reported. The number is calculating rate, which is the number of events (flares) over total participant-years (time period).
Time frame: Up to Week 52
Number of Participants With Adverse Events (AEs)
An AE was any untoward medical occurrence in a clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention.
Time frame: Up to Week 52
Number of Participants With Adverse Events of Special Interests (AESIs), Including Infusion-related Reactions (IRRs), Neutropenia, Infections, and Thrombocytopenia
AESIs for this study were as follows: cases of potential drug-induced liver injury that include an elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) in combination with either an elevated bilirubin or clinical jaundice; suspected transmission of an infectious agent by a study treatment (Hy's Law); IRRs (systemic IRRs only); grade \>=3 infections; any hepatitis B reactivation; progressive multifocal leukoencephalopathy (PML); study drug-related neutropenia; study drug-related thrombocytopenia; gastrointestinal (GI) perforations; worsening of preexisting cardiac conditions.
Time frame: Up to Week 52
Maximum Serum Concentration (Cmax) of Obinutuzumab
Cmax is defined as the maximum concentration of a drug in the serum. Cmax is reported at steady state. Hence, only one value for the specified assessment periods is reported here.
Time frame: From Weeks 0-24 and Weeks 24-52
Trough Concentration (Ctrough) of Obinutuzumab
Ctrough is defined as the concentration immediately prior to the next dose at steady state (end of the dosing interval). Data were collected when the participant attended the next dose administration visits over the two time intervals.
Time frame: From Weeks 0-24 and Weeks 24-52
Area Under the Concentration-time Curve (AUC) of Obinutuzumab
AUC is defined as the area under the drug concentration-time curve and represents drug exposure over a specified time interval. Data presented here give exposure over the duration of 0 to 52 weeks.
Time frame: Week 0-52
Number of Participants With Anti-drug Antibodies (ADAs) to Obinutuzumab
Participants who received obinutuzumab were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following obinutuzumab exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the titer of the baseline sample (treatment-enhanced ADA response). Participants with a positive post-baseline sample has been reported here.
Time frame: Up to Week 52
A total of 303 participants with active, autoantibody-positive systemic lupus erythematosus (SLE) treated with standard-of-care therapy took part in the study at 64 investigative sites across 14 countries. Participants were randomized in a 1:1 ratio to receive either obinutuzumab or placebo in the blinded treatment period.
| Milestone | Obinutuzumab | Placebo |
|---|---|---|
| Started | 151 | 152 |
| Safety-evaluable set | 151 | 151 |
| Completed | 144 | 136 |
| Not completed | 7 | 16 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Death | 1 | 3 |
| Withdrew: Lack of efficacy | 0 | 3 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Pregnancy | 0 | 1 |
| Withdrew: Withdrawal by subject | 5 | 4 |
Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of \>=4 points in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K); 2) No new systems or organs affected, as defined by \>=1 new British Isles Lupus Assessment Group (BILAG) A or \>=2 new BILAG B items compared with baseline; 3) No worsening from baseline of \>=0.30 points on a 3-point Physician's Global Assessment-Visual Analog Scale (PGA-VAS). SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).
| percentage of participants | Obinutuzumab | Placebo |
|---|---|---|
| Percentage of Participants Who Achieved SLE Responder Index (SRI4) at Week 52 | 76.7 (69.80 to 83.53) | 53.5 (45.33 to 61.60) |
Achieving BICLA was defined as all of the following: 1) Reduction of all baseline BILAG-2004 A items to B/C/D and baseline BILAG-2004 B items to C/D; 2) No new systems or organs affected, as defined by \>=1 new BILAG A or \>=2 new BILAG B items compared with baseline; 3) No net increase in SLEDAI-2K score from baseline; 4) No worsening from baseline of \>=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).
| percentage of participants | Obinutuzumab | Placebo |
|---|---|---|
| Percentage of Participants Who Achieved British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) at Week 52 | 62.0 (54.23 to 69.82) | 40.1 (32.12 to 48.07) |
Sustained OCS was defined as all of the following: 1) No treatment with prednisone \>7.5 mg/day (or equivalent) from Week 40 through Week 52; 2) No receipt of intravenous, intramuscular, or intra-articular corticosteroids from Week 40 through Week 52. Participants who experienced intercurrent events, including major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy, or AE, were considered nonresponders.
| percentage of participants | Obinutuzumab | Placebo |
|---|---|---|
| Percentage of Participants Who Achieved Sustained Oral Corticosteroid Control (OCS) (<=7.5 mg/Day) From Week 40 Through Week 52 | 80.0 (71.50 to 88.50) | 54.1 (43.52 to 64.71) |
Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of \>=4 points in the SLEDAI-2K; 2) No new systems or organs affected, as defined by \>=1 new BILAG A or \>=2 new BILAG B items compared with baseline; 3) No worsening from baseline of \>=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).
| percentage of participants | Obinutuzumab | Placebo |
|---|---|---|
| Percentage of Participants Who Achieved Sustained SRI(4) Response From Week 40 Through Week 52 | 72.0 (64.60 to 79.31) | 46.4 (38.29 to 54.57) |
Achieving SRI(6) was defined as all of the following: 1) Reduction from baseline of \>=4 points in the SLEDAI-2K; 2) No new systems or organs affected, as defined by \>=1 new BILAG A or \>=2 new BILAG B items compared with baseline; 3) No worsening from baseline of \>=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).
| percentage of participants | Obinutuzumab | Placebo |
|---|---|---|
| Percentage of Participants With SRI(6) Response at Week 52 | 68.9 (61.44 to 76.45) | 38.9 (30.98 to 46.85) |
BILAG flare was defined as the occurrence of \>=1 new BILAG A or \>=2 new BILAG B manifestations from the previous visit. BILAG Index assesses clinical signs, symptoms, and laboratory parameters related to SLE across 9 organ systems. Each organ system is scored alphabetically: A (severe disease), B (moderate disease), C (mild stable disease), D (inactive but previously active), and E (inactive and never affected). Participants who experienced major concomitant therapy violation, treatment failure requiring rescue medication, and lack of efficacy (regardless of discontinuation from treatment or study) were considered as having a flare at the time of the event. Participants who experienced early discontinuation from the blinded period due to reasons other than lack of efficacy and those who completed 52 week treatment period without flare were censored at the time of the event. Kaplan-Meier (KM) method was used to estimate the time to first BILAG flare.
| weeks | Obinutuzumab | Placebo |
|---|---|---|
| Time to BILAG Flare Over 52 Weeks | NA (NA to NA) | 52.3 (35.1 to NA) |
Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of \>=4 points in the SLEDAI-2K; 2) No new systems or organs affected, as defined by \>=1 new BILAG A or \>=2 new BILAG B items compared with baseline; 3) No worsening from baseline of \>=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).
| percentage of participants | Obinutuzumab | Placebo |
|---|---|---|
| Percentage of Participants Who Achieved SRI(4) at Week 24 | 73.5 | 55.9 |
Achieving SRI(4) was defined as all of the following: 1) Reduction from baseline of \>=4 points in the SLEDAI-2K, excluding points from the immunologic components (low complement and elevated anti-dsDNA antibody; 2) No new systems or organs affected, as defined by \>=1 new BILAG A or \>=2 new BILAG B items compared with baseline; 3) No worsening from baseline of \>=0.30 points on a 3-point PGA-VAS. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).
| percentage of participants | Obinutuzumab | Placebo |
|---|---|---|
| Percentage of Participants Who Achieved Clinical SRI(4) at Week 52 | 74.8 | 50.0 |
Achieving SRI(4) on low doses of corticosteroids was defined as all of the following: 1) Reduction from baseline of \>=4 points in SLEDAI-2K; 2) No new systems or organs affected, as defined by \>=1 new BILAG A or \>=2 new BILAG B items compared with baseline; 3) No worsening from baseline of \>=0.30 points on a 3-point PGA-VAS; 4) Prednisone \<=7.5 mg/day or equivalent. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).
| percentage of participants | Obinutuzumab | Placebo |
|---|---|---|
| Percentage of Participants Who Achieved SRI(4) at Week 52 on Low-dose of Corticosteroids | 74.2 | 47.4 |
LLDAS response was defined as achievement of all of the following: 1) SLEDAI-2K \<=4; 2) No SLEDAI-2K activity in major organ systems (renal, central nervous system, cardiopulmonary, vasculitis, fever) and no BILAG hemolytic anemia or gastrointestinal activity; 3) No new SLEDAI-2K activity compared with the previous assessment PGA-VAS \<=1; 4) Current prednisone dose \<=7.5 mg/day or equivalent. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor).
| percentage of participants | Obinutuzumab | Placebo |
|---|---|---|
| Percentage of Participants Who Achieved Lupus Low Disease Activity State (LLDAS) at Week 52 | 57.6 | 25.0 |
DORIS response was defined as achievement of all of the following: 1) Clinical SLEDAI-2K (cSLEDAI-2K) = 0, where cSLEDAI-2K is defined as total SLEDAI-2K score excluding anti-dsDNA and complement items; 2) PGA-VAS \<0.5; 3) Current prednisone dose \<=5 mg/day or equivalent. SLEDAI-2K assessment consists of 24 items with total score of 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. PGA assesses disease activity on a VAS = from 0 (very well) to 100 (very poor). Participants who experienced intercurrent events, including major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy or AE, were considered nonresponders.
| percentage of participants | Obinutuzumab | Placebo |
|---|---|---|
| Percentage of Participants Who Achieved Definition of Remission in SLE (DORIS) at Week 52 | 33.8 | 13.8 |
The FACIT-F was a patient-completed questionnaire consisting of 13 items that assessed fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as: 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). Adjusted mean values have been reported. The analysis was performed using analysis of covariance (ANCOVA) model.
| score on a scale | Obinutuzumab | Placebo |
|---|---|---|
| Change at Week 24 | 6.82 ± 0.828 | 5.64 ± 0.842 |
| Change at Week 52 | 8.44 ± 0.777 | 5.66 ± 0.805 |
The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status. Adjusted mean values have been reported. The analysis was performed using ANCOVA model.
| score on a scale | Obinutuzumab | Placebo |
|---|---|---|
| Change at Week 24 | 7.06 ± 0.786 | 4.46 ± 0.790 |
| Change at Week 52 | 8.11 ± 0.757 | 5.60 ± 0.760 |
The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and the MCS. The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status. Adjusted mean values have been reported. The analysis was performed using ANCOVA model.
| score on a scale | Obinutuzumab | Placebo |
|---|---|---|
| Change at Week 24 | 5.98 ± 0.640 | 4.21 ± 0.641 |
| Change at Week 52 | 6.97 ± 0.659 | 5.46 ± 0.661 |
Active joint was defined as a joint that is both swollen and tender. A 28-joint count of swollen and tender joints was performed in this study. Data after the first occurrence of intercurrent event (ICE), including major concomitant therapy violation, treatment failure requiring rescue medication or early discontinuation from the blinded period due to AE, death and lack of efficacy, was imputed using the worst post-baseline value from the following assessments: the last value available prior to the occurrence of the first ICE; all values available after the occurrence of the ICE. Participants with treatment discontinuation without any ICE above were evaluated under the treatment policy strategy. Adjusted mean values have been reported. The analysis was performed using ANCOVA model.
| active joints | Obinutuzumab | Placebo |
|---|---|---|
| Change at Week 24 | -5.70 ± 0.347 | -5.44 ± 0.348 |
| Change at Week 52 | -6.42 ± 0.319 | -5.69 ± 0.319 |
Active joint was defined as a joint that is both swollen and tender. A 28-joint count of swollen and tender joints was performed in this study. Participants who experienced major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy or AE were considered non-responders.
| percentage of participants | Obinutuzumab | Placebo |
|---|---|---|
| Week 24 | 80.5 | 72.6 |
| Week 28 | 85.2 | 74.2 |
| Week 32 | 83.6 | 72.6 |
| Week 36 | 84.4 | 74.2 |
| Week 40 | 83.6 | 73.4 |
| Week 44 | 82.8 | 69.4 |
| Week 48 | 83.6 | 68.5 |
| Week 52 | 80.5 | 66.1 |
CLASI is a validated instrument for assessing cutaneous lupus erythematosus activity. It reports two global scores: one for current inflammatory activity (Total Activity Score), and one for damage (Total Damage Score). To calculate the total scores, trained assessors evaluate erythema, scale/hypertrophy, dyspigmentation, and scarring/atrophy/panniculitis at 13 anatomic locations plus additional assessments for mucosal lesions and alopecia. CLASI total activity score ranges from 0 to 70, with higher scores indicating increased disease severity. Participants who experienced major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy or AE were considered non-responders.
| percentage of participants | Obinutuzumab | Placebo |
|---|---|---|
| Week 24 | 67.9 | 58.0 |
| Week 28 | 73.6 | 60.0 |
| Week 32 | 73.6 | 58.0 |
| Week 36 | 71.7 | 60.0 |
| Week 40 | 73.6 | 60.0 |
| Week 44 | 71.7 | 56.0 |
| Week 48 | 71.7 | 56.0 |
| Week 52 | 66.0 | 58.0 |
Sustained OCS was defined as all of the following: 1) No treatment with prednisone \>5 mg/day (or equivalent) from Week 40 through Week 52; 2) No receipt of intravenous, intramuscular, or intra-articular corticosteroids from Week 40 through Week 52. Participants who experienced intercurrent events, including major concomitant therapy violation, treatment failure requiring rescue medication, and discontinuation from the double-blinded period due to death, lack of efficacy, or AE, were considered nonresponders.
| percentage of participants | Obinutuzumab | Placebo |
|---|---|---|
| Percentage of Participants Who Achieved Sustained OCS (<=5 mg/Day) From Week 40 Through Week 52 | 72.9 (63.50 to 82.39) | 49.4 (38.78 to 60.04) |
Cumulative oral corticosteroid was represented in prednisone or equivalent only. The mean of the standardized area under the curve (AUC) through Week 52 have been reported. AUC was derived based on the actual dose participants have received. Standardized AUC was derived using AUC divided by days in study multiplied by 365.25 days for each participant.
| mg | Obinutuzumab | Placebo |
|---|---|---|
| Cumulative Corticosteroid Use Through Week 52 | 2422.2 ± 1421.0 | 2739.0 ± 1495.4 |
BILAG flare was defined as the occurrence of \>=1 new BILAG A or \>=2 new BILAG B manifestations from the previous visit. BILAG Index assesses clinical signs, symptoms, and laboratory parameters related to SLE across 9 organ systems. Each organ system is scored alphabetically: A (severe disease), B (moderate disease), C (mild stable disease), D (inactive but previously active), and E (inactive and never affected). The number of flares over the 52-week blinded treatment period has been reported. The number is calculating rate, which is the number of events (flares) over total participant-years (time period).
| flares per participant-year | Obinutuzumab | Placebo |
|---|---|---|
| Annualized Flare Rate Through Week 52 | 0.38 (0.28 to 0.51) | 0.62 (0.48 to 0.81) |
An AE was any untoward medical occurrence in a clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention.
| Participants | Obinutuzumab | Placebo |
|---|---|---|
| Number of Participants With Adverse Events (AEs) | 134 | 123 |
AESIs for this study were as follows: cases of potential drug-induced liver injury that include an elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) in combination with either an elevated bilirubin or clinical jaundice; suspected transmission of an infectious agent by a study treatment (Hy's Law); IRRs (systemic IRRs only); grade \>=3 infections; any hepatitis B reactivation; progressive multifocal leukoencephalopathy (PML); study drug-related neutropenia; study drug-related thrombocytopenia; gastrointestinal (GI) perforations; worsening of preexisting cardiac conditions.
| Participants | Obinutuzumab | Placebo |
|---|---|---|
| IRRs | 18 | 5 |
| Grade 3 or Higher Infections | 11 | 7 |
| Drug-related Neutropenia | 7 | 3 |
| Drug-related Thrombocytopenia | 0 | 0 |
| Gastrointestinal Perforations | 0 | 1 |
| Hy's Law | 0 | 1 |
| Worsening of Pre-existing Cardiac Conditions | 0 | 0 |
| Any Hepatitis B Reactivation or PML | 0 | 0 |
Cmax is defined as the maximum concentration of a drug in the serum. Cmax is reported at steady state. Hence, only one value for the specified assessment periods is reported here.
| micrograms per milliliter (μg/mL) | Obinutuzumab |
|---|---|
| Week 0-24 | 557 ± 28.3 |
| Week 24-52 | 603 ± 26.5 |
Ctrough is defined as the concentration immediately prior to the next dose at steady state (end of the dosing interval). Data were collected when the participant attended the next dose administration visits over the two time intervals.
| μg/mL | Obinutuzumab |
|---|---|
| Week 0-24 | 1.74 ± 131 |
| Week 24-52 | 1.72 ± 183 |
AUC is defined as the area under the drug concentration-time curve and represents drug exposure over a specified time interval. Data presented here give exposure over the duration of 0 to 52 weeks.
| μg/mL*day | Obinutuzumab |
|---|---|
| Area Under the Concentration-time Curve (AUC) of Obinutuzumab | 51600 ± 27.3 |
Participants who received obinutuzumab were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following obinutuzumab exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the titer of the baseline sample (treatment-enhanced ADA response). Participants with a positive post-baseline sample has been reported here.
| Participants | Obinutuzumab |
|---|---|
| Number of Participants With Anti-drug Antibodies (ADAs) to Obinutuzumab | 5 |
Collected over All-cause Mortality: Up to primary clinical cut-off (approximately 46 months) SAEs and Other AEs: Up to Week 52. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Obinutuzumab 1000mg | 1/151 (0.7%) | 24/151 (15.9%) | 92/151 (60.9%) |
| Placebo | 5/151 (3.3%) | 18/151 (11.9%) | 76/151 (50.3%) |
| Event | Obinutuzumab 1000mg | Placebo |
|---|---|---|
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 1/151 | 6/151 |
| PneumoniaInfections and infestations | 3/151 | 3/151 |
| Chest painGeneral disorders | 0/151 | 2/151 |
| GastroenteritisInfections and infestations | 0/151 | 2/151 |
| SepsisInfections and infestations | 1/151 | 2/151 |
| Upper respiratory tract infectionInfections and infestations | 2/151 | 0/151 |
| Urinary tract infectionInfections and infestations | 2/151 | 0/151 |
| Infusion related reactionInjury, poisoning and procedural complications | 2/151 | 0/151 |
| AnaemiaBlood and lymphatic system disorders | 1/151 | 1/151 |
| NeutropeniaBlood and lymphatic system disorders | 1/151 | 1/151 |
| Event | Obinutuzumab 1000mg | Placebo |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 27/151 | 19/151 |
| Urinary tract infectionInfections and infestations | 24/151 | 17/151 |
| Infusion related reactionInjury, poisoning and procedural complications | 14/151 | 5/151 |
| DiarrhoeaGastrointestinal disorders | 7/151 | 13/151 |
| NasopharyngitisInfections and infestations | 13/151 | 7/151 |
| HeadacheNervous system disorders | 11/151 | 13/151 |
| AnaemiaBlood and lymphatic system disorders | 5/151 | 11/151 |
| BronchitisInfections and infestations | 9/151 | 8/151 |
| COVID-19Infections and infestations | 9/151 | 6/151 |
| PharyngitisInfections and infestations | 8/151 | 6/151 |
Efficacy-evaluable (EE) set included all randomized participants, with participants grouped according to assigned treatment.
| Age, Continuous(years) | Obinutuzumab | Placebo | Total |
|---|---|---|---|
| Mean | 41.1 ± 12.3 | 41.4 ± 12.6 | 41.2 ± 12.4 |
| Sex: Female, Male(Participants) | Obinutuzumab | Placebo | Total |
|---|---|---|---|
| Female | 139 | 135 | 274 |
| Male | 12 | 17 | 29 |
| Ethnicity (NIH/OMB)(Participants) | Obinutuzumab | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 75 | 86 | 161 |
| Not Hispanic or Latino | 73 | 65 | 138 |
| Unknown or Not Reported | 3 | 1 | 4 |
| Race (NIH/OMB)(Participants) | Obinutuzumab | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 44 | 42 | 86 |
| Asian | 4 | 2 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 22 | 25 | 47 |
| White | 64 | 62 | 126 |
| More than one race | 7 | 11 | 18 |
| Unknown or Not Reported | 10 | 9 | 19 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from Oct 2021 to primary completion in Sep 2025, 46 months.
Results were first posted in Nov 2026, 1 year 1 month after primary completion.
Of 53 phase 3 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's 46 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Obinutuzumab
Lupus Erythematosus, Systemic →